Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Is The Rhinovirus Infections Drug Market Expected To Grow In Terms Of Size?

In recent years, the market size for drugs treating rhinovirus infections has shown robust growth. The value of this market is anticipated to climb from $1.26 billion in 2024 to $1.36 billion in 2025, marking a Compound Annual Growth Rate (CAGR) of 7.7%. Factors like the increased occurrence of the common cold, enhanced knowledge regarding respiratory infections, rising need for over-the-counter medications, escalated healthcare spending, and the growing acceptance of combination therapies can be credited for this growth during the historic period.

The market for rhinovirus infections medications is predicted to witness substantial growth over the next few years, expanding to $1.89 billion in 2029 with a compound annual growth rate (CAGR) of 8.7%. This growth during the forecast period may be due to an increase in antiviral drugs investment, a rising demand for specific therapies, the mounting prevalence of respiratory diseases, broader healthcare access in emerging markets, and a heightened usage of biologics and monoclonal antibodies. Trends to watch for in the forecast period encompass progression in antiviral research, vaccine research advancements, innovation in biologics and monoclonal antibodies, the creation of broad-spectrum antivirals, and the ongoing breakthroughs in nanotechnology for drug delivery.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23503&type=smp

Which Key Factors Are Fueling Growth In The Rhinovirus Infections Drug Market?

The surge in respiratory illnesses is anticipated to boost the expansion of the rhinovirus infections drug market in the near future. These ailments, which include asthma, chronic obstructive pulmonary disease (COPD), and pneumonia, have an impact on the lungs and air passages and cause breathing complications. The escalation of such disorders can be attributed mainly to the growth in air pollution and being exposed to occupational risks. These factors result in conditions like asthma, COPD, and pneumonia becoming more widespread among the affected groups of people. Drugs for rhinovirus infections aid respiratory disorders by focusing on viral replication, lessening inflammation, and relieving symptoms to enhance respiratory functioning. For instance, data from the National Asthma Council, a non-profit organization from Australia, in November 2023, showed that 467 asthma-linked deaths occurred in Australia in 2022, which involved 299 women and 168 men. This was a rise from 355 deaths in 2021. Thus, the escalating occurrence of respiratory disorders is propelling growth in the rhinovirus infections drug market.

Which Segmentation Factors Are Critical In The Rhinovirus Infections Drug Market Analysis?

The rhinovirus infections drug market covered in this report is segmented –

1) By Product: Antivirals, Immunomodulators, Vaccines, Nasal Sprays, Symptomatic Treatments

2) By Patient Age Group: Infants, Children, Adults, Elderly

3) By Route Of Administration: Oral, Intranasal, Injectable

4) By Indication: Common Cold, Asthma Exacerbation, Chronic Obstructive Pulmonary Disease (COPD) Exacerbation, Other Indications

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies

Subsegments:

1) By Antivirals: Pleconaril, Vapendavir, Rupintrivir, Other Antivirals

2) By Immunomodulators: Interferons, Toll-Like Receptor Agonists, Other Immunomodulators

3) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines

4) By Nasal Sprays: Antihistamine Nasal Sprays, Decongestant Nasal Sprays, Steroid Nasal Sprays, Saline Nasal Sprays

5) By Symptomatic Treatments: Analgesics, Antipyretics, Cough Suppressants, Expectorants, Antihistamines

What Are The Dominant Trends Currently Seen In The Rhinovirus Infections Drug Market?

In the rhinovirus infections drug market, major players are concentrating their efforts on the development of innovative products such as antiviral medications. The purpose of this focus is to improve treatment effectiveness, lessen the severity of symptoms, and hasten patient recovery. Antiviral drugs work by stifling the replication of viruses within the human body and can be effective against viruses such as influenza, HIV, hepatitis, and rhinovirus. Some of these drugs function by preventing viruses from entering host cells, while others stop viral replication or assembly. For instance, in March 2025, the U.S. Food and Drug Administration (FDA) gave clearance to Altesa BioSciences Inc., a biotechnology company based in the US, for its Investigational New Drug (IND) application for vapendavir. This is an oral, broad-spectrum antiviral drug intended to treat rhinovirus infections in individuals with COPD. Vapendavir works to prevent rhinovirus from entering human cells and replicating, thereby proving effective against 97% of rhinoviruses and other respiratory enteroviruses. Altesa BioSciences has exclusive global rights to the development, production, and sale of vapendavir. The drug targets vulnerable populations, including those suffering from COPD and asthma, providing them with tailored treatment.

Which Companies Hold A Competitive Edge In The 599 Market?

Major companies operating in the rhinovirus infections drug market are Pfizer Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., BioFire Diagnostics LLC, hVIVO Services Limited, Romark Laboratories L.C., Cocrystal Pharma Inc., Altamira Therapeutics Ltd., Biota Pharmaceuticals Inc., Aditum Bio Management Company LLC, MetP Pharma AG, Via Nova Therapeutics Inc., Maxwell Biosciences Inc., Altesa BioSciences Inc., Apollo Therapeutics Group Limited, AIM ImmunoTech Inc., Bakar Labs, Ntvirin Pharma, bioRxiv, Pneumagen Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/rhinovirus-infections-drug-global-market-report

Which Region Is Leading Innovation In The Rhinovirus Infections Drug Market?

North America was the largest region in the rhinovirus infection drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rhinovirus infections drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=23503&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model